Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 15.53 Delayed Data As of Sep 23 |  +0.03 / +0.19%Today’s Change | 6.04 Today|||52-Week Range 16.32 | +38.66% Year-to-Date |
| Previous close | 15.50 |
| Today’s open | 15.50 |
| Day’s range | 15.31 - 16.00 |
| Volume | 32,523 |
| Average volume (3 months) | 33,094 |
| Market cap | $161.5M |
| Dividend yield | -- |
| Earnings growth (last year) | -15.03% |
| Earnings growth (this year) | -5.53% |
| Earnings growth (next 5 years) | +40.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 5.19 |
| Today’s change | Today’s % change | |
|---|---|---|
| AGTCApplied Genetic Tech... | +0.07 | +0.79% |
| SYNSynthetic Biologics ... | -0.02 | -1.13% |
| NYMXNymox Pharmaceutical... | -0.02 | -0.58% |
| GLYCGlycoMimetics Inc | -0.09 | -1.23% |
| Next reporting date | November 9, 2016 |
| EPS forecast (this quarter) | -$0.55 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$18.7M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, CEO, Secretary & Director David P. Luci |
Vice President-Finance & Corporate Development David Garrett |
Corporate headquarters New York, New York |
